Publication

Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer

Mohamadkhani, A., Naderi, E., Sharafkhah, M., Fazli, H. R., Moradzadeh, M. & Pourshams, A., 2013, In : JAMA oncology. 2013, 6 p., 738915.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Mohamadkhani, A., Naderi, E., Sharafkhah, M., Fazli, H. R., Moradzadeh, M., & Pourshams, A. (2013). Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. JAMA oncology, 2013, [738915]. https://doi.org/10.1155/2013/738915

Author

Mohamadkhani, Ashraf ; Naderi, Elnaz ; Sharafkhah, Maryam ; Fazli, Hamid Reza ; Moradzadeh, Malihe ; Pourshams, Akram. / Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. In: JAMA oncology. 2013 ; Vol. 2013.

Harvard

Mohamadkhani, A, Naderi, E, Sharafkhah, M, Fazli, HR, Moradzadeh, M & Pourshams, A 2013, 'Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer', JAMA oncology, vol. 2013, 738915. https://doi.org/10.1155/2013/738915

Standard

Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. / Mohamadkhani, Ashraf; Naderi, Elnaz; Sharafkhah, Maryam; Fazli, Hamid Reza; Moradzadeh, Malihe; Pourshams, Akram.

In: JAMA oncology, Vol. 2013, 738915, 2013.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Mohamadkhani A, Naderi E, Sharafkhah M, Fazli HR, Moradzadeh M, Pourshams A. Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. JAMA oncology. 2013;2013. 738915. https://doi.org/10.1155/2013/738915


BibTeX

@article{dbd14e2050c942daa769ee3e703dfc8a,
title = "Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer",
abstract = "The TP53 gene encodes tumor protein p53 which play a major role in the etiology of pancreatic cancer. The important role of codon 249 of TP53 for binding of p53 to its sequence-specific consensus site in DNA has been revealed by crystallography's studies, and mutation at this codon was detected in the plasma of some human cancers. The TP53 Mut assessor software within the International Agency for Research on Cancer (IARC) TP53 Database was performed to evaluate every possible mutation at codon 249. DNA was extracted from the plasma of 133 pancreatic cancer patients and 85 noncancer-bearing individuals. Exon 7 in TP53 was amplified, and mutation at R249 was identified by the endonuclease cleavage of HaeIII. The group of patients showed a frequency of 11% (22 of 133 samples) R249 mutation compared to 3.5% (3 of 85 samples) in the group of control which was significant (P = 0.03). This mutation demonstrated statistically significant association with pancreatic cancer risk in unadjusted odds ratio (OR: 3.74, 95% CI: 1.1-13.2; P = 0.041); however when adjusted for confounding factors, it was marginally significant because of lower control samples. These findings demonstrate that mutation at R249 of TP53 can be considered for increasing risk of pancreatic cancer that needs more research. ",
author = "Ashraf Mohamadkhani and Elnaz Naderi and Maryam Sharafkhah and Fazli, {Hamid Reza} and Malihe Moradzadeh and Akram Pourshams",
year = "2013",
doi = "10.1155/2013/738915",
language = "English",
volume = "2013",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "AMER MEDICAL ASSOC",

}

RIS

TY - JOUR

T1 - Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer

AU - Mohamadkhani, Ashraf

AU - Naderi, Elnaz

AU - Sharafkhah, Maryam

AU - Fazli, Hamid Reza

AU - Moradzadeh, Malihe

AU - Pourshams, Akram

PY - 2013

Y1 - 2013

N2 - The TP53 gene encodes tumor protein p53 which play a major role in the etiology of pancreatic cancer. The important role of codon 249 of TP53 for binding of p53 to its sequence-specific consensus site in DNA has been revealed by crystallography's studies, and mutation at this codon was detected in the plasma of some human cancers. The TP53 Mut assessor software within the International Agency for Research on Cancer (IARC) TP53 Database was performed to evaluate every possible mutation at codon 249. DNA was extracted from the plasma of 133 pancreatic cancer patients and 85 noncancer-bearing individuals. Exon 7 in TP53 was amplified, and mutation at R249 was identified by the endonuclease cleavage of HaeIII. The group of patients showed a frequency of 11% (22 of 133 samples) R249 mutation compared to 3.5% (3 of 85 samples) in the group of control which was significant (P = 0.03). This mutation demonstrated statistically significant association with pancreatic cancer risk in unadjusted odds ratio (OR: 3.74, 95% CI: 1.1-13.2; P = 0.041); however when adjusted for confounding factors, it was marginally significant because of lower control samples. These findings demonstrate that mutation at R249 of TP53 can be considered for increasing risk of pancreatic cancer that needs more research.

AB - The TP53 gene encodes tumor protein p53 which play a major role in the etiology of pancreatic cancer. The important role of codon 249 of TP53 for binding of p53 to its sequence-specific consensus site in DNA has been revealed by crystallography's studies, and mutation at this codon was detected in the plasma of some human cancers. The TP53 Mut assessor software within the International Agency for Research on Cancer (IARC) TP53 Database was performed to evaluate every possible mutation at codon 249. DNA was extracted from the plasma of 133 pancreatic cancer patients and 85 noncancer-bearing individuals. Exon 7 in TP53 was amplified, and mutation at R249 was identified by the endonuclease cleavage of HaeIII. The group of patients showed a frequency of 11% (22 of 133 samples) R249 mutation compared to 3.5% (3 of 85 samples) in the group of control which was significant (P = 0.03). This mutation demonstrated statistically significant association with pancreatic cancer risk in unadjusted odds ratio (OR: 3.74, 95% CI: 1.1-13.2; P = 0.041); however when adjusted for confounding factors, it was marginally significant because of lower control samples. These findings demonstrate that mutation at R249 of TP53 can be considered for increasing risk of pancreatic cancer that needs more research.

U2 - 10.1155/2013/738915

DO - 10.1155/2013/738915

M3 - Article

C2 - 24489544

VL - 2013

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

M1 - 738915

ER -

ID: 136420438